2024
Innovation in Alopecia Areata
Kalil L, King B. Innovation in Alopecia Areata. Dermatologic Clinics 2024, 43: 27-33. PMID: 39542562, DOI: 10.1016/j.det.2024.09.001.Peer-Reviewed Original ResearchDermatology resident comfort level treating hair conditions related to patients with skin of color
Tolliver S, Cascardo C, Wong N, Abushukur Y, Potts G. Dermatology resident comfort level treating hair conditions related to patients with skin of color. International Journal Of Women's Dermatology 2024, 10: e137. PMID: 38873622, PMCID: PMC11168838, DOI: 10.1097/jw9.0000000000000137.Peer-Reviewed Original ResearchInstitutional review board-approved surveyResident comfort levelSkin of colorComfort levelPotential recall biasCare knowledgeUnited States residentsRecall biasResidents' knowledgeDermatology programsResident satisfactionState residentsCareDermatology residentsResidentsSample sizeAlopecia areataKnowledge gapsAndrogenetic alopeciaDermatologyPatientsTrichorrhexis nodosaAlopeciaHair conditionTreatment
2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore gradeHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancer
2022
Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment
2021
Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.
Williams N, Paxman R, Thornhill E, Kassem M, Grimm M, Dulmage B, Cathcart-Rake E, Ruddy K, Pariser A, Gatti-Mays M, Cherian M, VanDeusen J, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Loprinzi C, Lustberg M. Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. Journal Of Clinical Oncology 2021, 39: e18739-e18739. DOI: 10.1200/jco.2021.39.15_suppl.e18739.Peer-Reviewed Original ResearchScalp coolingNational Comprehensive Cancer NetworkMedical Oncology guidelinesComprehensive Cancer NetworkMajority of patientsOncology guidelinesCategory 2ABreast cancerHair lossCancer NetworkSide effectsChemotherapyLargest reportPatientsReal-world useOlder adultsScalpEuropean SocietyFurther studiesAlopeciaCancerDescriptive statisticsGenitourinaryLungGynecology
2020
Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States
Singer S, Tkachenko E, Sharma P, Nelson C, Mostaghimi A, LeBoeuf NR. Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. Journal Of The American Academy Of Dermatology 2020, 85: 1248-1252. PMID: 32610170, DOI: 10.1016/j.jaad.2020.06.073.Peer-Reviewed Original Research
2016
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk Y, Shkolnik E, Nesterov V, Shkolnik L, Varlan G. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity]. Kardiologiia 2016, 56: 72-79. PMID: 28290807.Peer-Reviewed Original ResearchConceptsPrevention of anthracycline cardiotoxicityMolecular targeted therapySevere side effectsAnthracycline administrationAnthracycline cardiotoxicityChemotherapeutic agentsChemotherapeutic drugsClinical studiesSide effectsAntineoplastic drugsAnthracyclinesCardiotoxicityEarly detectionDrugMyelotoxicityMalignancyEpirubicinThromboembolismTherapyAclarubicinAgentsAlopeciaDaunorubicinDoxorubicinCancer
2015
Nail lichen planus in a patient with alopecia totalis.
Ginsberg B, Yost J, Lewin J, Hale C, Meehan S, Carucci J, Ramachandran S. Nail lichen planus in a patient with alopecia totalis. Dermatology Online Journal 2015, 20 PMID: 25526340, DOI: 10.5070/d32012025061.Peer-Reviewed Original ResearchConceptsLichen planusAlopecia totalisAnti-inflammatory treatmentNail lichen planusNon-scarring alopeciaCommon dermatologic disorderThree-year historyGlucocorticoid injectionHistopathologic featuresUncommon subtypeDermatologic disordersNail matrixPlanusTotalisPatientsBiopsyAlopeciaPathogenesesSubtypesDystrophy
2013
Early-Onset Alopecia and Amyotrophic Lateral Sclerosis: A Cohort Study
Fondell E, Fitzgerald KC, Falcone GJ, O'Reilly É, Ascherio A. Early-Onset Alopecia and Amyotrophic Lateral Sclerosis: A Cohort Study. American Journal Of Epidemiology 2013, 178: 1146-1149. PMID: 23942216, PMCID: PMC3783095, DOI: 10.1093/aje/kwt096.Peer-Reviewed Original ResearchConceptsAge 45 yearsEarly-onset alopeciaRisk of ALSExtensive alopeciaTAR DNA-binding protein 43DNA-binding protein 43Health Professionals FollowAmyotrophic lateral sclerosisEarly baldingProfessionals FollowCohort studyModerate alopeciaProtein 43Large cohortHigh riskLateral sclerosisUS menAlopeciaSingle nucleotide polymorphism (SNP) variantsPolymorphism variantsALSMenFurther investigationRiskBalding
2006
The histopathology of primary cicatricial alopecia.
Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Seminars In Cutaneous Medicine And Surgery 2006, 25: 41-50. PMID: 16616302, DOI: 10.1016/j.sder.2006.01.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2004
Vogt-Koyanagi-Harada Syndrome and Ulcerative Colitis
Federman DG, Kravetz JD, Ruser CB, Judson PH, Kirsner RS. Vogt-Koyanagi-Harada Syndrome and Ulcerative Colitis. Southern Medical Journal 2004, 97: 169-171. PMID: 14982267, DOI: 10.1097/01.smj.0000100263.99708.10.Peer-Reviewed Case Reports and Technical NotesConceptsVKH syndromeUlcerative colitisHarada syndromeVogt-KoyanagiSevere ulcerative colitisTraumatic brain injuryImmunologic milieuReactive arthritisAutoimmune disordersUncommon disorderBrain injuryPatient historyCutaneous abnormalitiesSyndromeColitisDisordersUveitisArthritisTinnitusVertigoHeadacheMeningoencephalitisPatientsPoliosisAlopecia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply